Copyright Reports & Markets. All rights reserved.

Global Plasma Protease C1-inhibitor Treatment Market Professional Survey Report 2019

Request for Sample of this report
Buy now

Table of Contents

    Executive Summary

      1 Industry Overview of Plasma Protease C1-inhibitor Treatment

      • 1.1 Definition of Plasma Protease C1-inhibitor Treatment
      • 1.2 Plasma Protease C1-inhibitor Treatment Segment by Drug Class
        • 1.2.1 Global Plasma Protease C1-inhibitor Treatment Production Growth Rate Comparison by Drug Class (2014-2025)
        • 1.2.2 C1-inhibitors
        • 1.2.3 Kallikrein Inhibitor (Kalbitor)
        • 1.2.4 Selective Bradykinin B2 Receptor Antagonist (Firazyr)
      • 1.3 Plasma Protease C1-inhibitor Treatment Segment by Applications
        • 1.3.1 Global Plasma Protease C1-inhibitor Treatment Consumption Comparison by Applications (2014-2025)
        • 1.3.2 Hospital Pharmacies
        • 1.3.3 Independent Pharmacies and Outlets
      • 1.4 Global Plasma Protease C1-inhibitor Treatment Overall Market
        • 1.4.1 Global Plasma Protease C1-inhibitor Treatment Revenue (2014-2025)
        • 1.4.2 Global Plasma Protease C1-inhibitor Treatment Production (2014-2025)
        • 1.4.3 North America Plasma Protease C1-inhibitor Treatment Status and Prospect (2014-2025)
        • 1.4.4 Europe Plasma Protease C1-inhibitor Treatment Status and Prospect (2014-2025)
        • 1.4.5 China Plasma Protease C1-inhibitor Treatment Status and Prospect (2014-2025)
        • 1.4.6 Japan Plasma Protease C1-inhibitor Treatment Status and Prospect (2014-2025)
        • 1.4.7 Southeast Asia Plasma Protease C1-inhibitor Treatment Status and Prospect (2014-2025)
        • 1.4.8 India Plasma Protease C1-inhibitor Treatment Status and Prospect (2014-2025)

      2 Manufacturing Cost Structure Analysis

      • 2.1 Raw Material and Suppliers
      • 2.2 Manufacturing Cost Structure Analysis of Plasma Protease C1-inhibitor Treatment
      • 2.3 Manufacturing Process Analysis of Plasma Protease C1-inhibitor Treatment
      • 2.4 Industry Chain Structure of Plasma Protease C1-inhibitor Treatment

      3 Development and Manufacturing Plants Analysis of Plasma Protease C1-inhibitor Treatment

      • 3.1 Capacity and Commercial Production Date
      • 3.2 Global Plasma Protease C1-inhibitor Treatment Manufacturing Plants Distribution
      • 3.3 Major Manufacturers Technology Source and Market Position of Plasma Protease C1-inhibitor Treatment
      • 3.4 Recent Development and Expansion Plans

      4 Key Figures of Major Manufacturers

      • 4.1 Plasma Protease C1-inhibitor Treatment Production and Capacity Analysis
      • 4.2 Plasma Protease C1-inhibitor Treatment Revenue Analysis
      • 4.3 Plasma Protease C1-inhibitor Treatment Price Analysis
      • 4.4 Market Concentration Degree

      5 Plasma Protease C1-inhibitor Treatment Regional Market Analysis

      • 5.1 Plasma Protease C1-inhibitor Treatment Production by Regions
        • 5.1.1 Global Plasma Protease C1-inhibitor Treatment Production by Regions
        • 5.1.2 Global Plasma Protease C1-inhibitor Treatment Revenue by Regions
      • 5.2 Plasma Protease C1-inhibitor Treatment Consumption by Regions
      • 5.3 North America Plasma Protease C1-inhibitor Treatment Market Analysis
        • 5.3.1 North America Plasma Protease C1-inhibitor Treatment Production
        • 5.3.2 North America Plasma Protease C1-inhibitor Treatment Revenue
        • 5.3.3 Key Manufacturers in North America
        • 5.3.4 North America Plasma Protease C1-inhibitor Treatment Import and Export
      • 5.4 Europe Plasma Protease C1-inhibitor Treatment Market Analysis
        • 5.4.1 Europe Plasma Protease C1-inhibitor Treatment Production
        • 5.4.2 Europe Plasma Protease C1-inhibitor Treatment Revenue
        • 5.4.3 Key Manufacturers in Europe
        • 5.4.4 Europe Plasma Protease C1-inhibitor Treatment Import and Export
      • 5.5 China Plasma Protease C1-inhibitor Treatment Market Analysis
        • 5.5.1 China Plasma Protease C1-inhibitor Treatment Production
        • 5.5.2 China Plasma Protease C1-inhibitor Treatment Revenue
        • 5.5.3 Key Manufacturers in China
        • 5.5.4 China Plasma Protease C1-inhibitor Treatment Import and Export
      • 5.6 Japan Plasma Protease C1-inhibitor Treatment Market Analysis
        • 5.6.1 Japan Plasma Protease C1-inhibitor Treatment Production
        • 5.6.2 Japan Plasma Protease C1-inhibitor Treatment Revenue
        • 5.6.3 Key Manufacturers in Japan
        • 5.6.4 Japan Plasma Protease C1-inhibitor Treatment Import and Export
      • 5.7 Southeast Asia Plasma Protease C1-inhibitor Treatment Market Analysis
        • 5.7.1 Southeast Asia Plasma Protease C1-inhibitor Treatment Production
        • 5.7.2 Southeast Asia Plasma Protease C1-inhibitor Treatment Revenue
        • 5.7.3 Key Manufacturers in Southeast Asia
        • 5.7.4 Southeast Asia Plasma Protease C1-inhibitor Treatment Import and Export
      • 5.8 India Plasma Protease C1-inhibitor Treatment Market Analysis
        • 5.8.1 India Plasma Protease C1-inhibitor Treatment Production
        • 5.8.2 India Plasma Protease C1-inhibitor Treatment Revenue
        • 5.8.3 Key Manufacturers in India
        • 5.8.4 India Plasma Protease C1-inhibitor Treatment Import and Export

      6 Plasma Protease C1-inhibitor Treatment Segment Market Analysis (by Type)

      • 6.1 Global Plasma Protease C1-inhibitor Treatment Production by Type
      • 6.2 Global Plasma Protease C1-inhibitor Treatment Revenue by Type
      • 6.3 Plasma Protease C1-inhibitor Treatment Price by Type

      7 Plasma Protease C1-inhibitor Treatment Segment Market Analysis (by Application)

      • 7.1 Global Plasma Protease C1-inhibitor Treatment Consumption by Application
      • 7.2 Global Plasma Protease C1-inhibitor Treatment Consumption Market Share by Application (2014-2019)

      8 Plasma Protease C1-inhibitor Treatment Major Manufacturers Analysis

      • 8.1 Shire plc
        • 8.1.1 Shire plc Plasma Protease C1-inhibitor Treatment Production Sites and Area Served
        • 8.1.2 Shire plc Product Introduction, Application and Specification
        • 8.1.3 Shire plc Plasma Protease C1-inhibitor Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.1.4 Main Business and Markets Served
      • 8.2 CSL Limited
        • 8.2.1 CSL Limited Plasma Protease C1-inhibitor Treatment Production Sites and Area Served
        • 8.2.2 CSL Limited Product Introduction, Application and Specification
        • 8.2.3 CSL Limited Plasma Protease C1-inhibitor Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.2.4 Main Business and Markets Served
      • 8.3 Sanquin
        • 8.3.1 Sanquin Plasma Protease C1-inhibitor Treatment Production Sites and Area Served
        • 8.3.2 Sanquin Product Introduction, Application and Specification
        • 8.3.3 Sanquin Plasma Protease C1-inhibitor Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.3.4 Main Business and Markets Served
      • 8.4 Pharming Group N.V.
        • 8.4.1 Pharming Group N.V. Plasma Protease C1-inhibitor Treatment Production Sites and Area Served
        • 8.4.2 Pharming Group N.V. Product Introduction, Application and Specification
        • 8.4.3 Pharming Group N.V. Plasma Protease C1-inhibitor Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.4.4 Main Business and Markets Served

      9 Development Trend of Analysis of Plasma Protease C1-inhibitor Treatment Market

      • 9.1 Global Plasma Protease C1-inhibitor Treatment Market Trend Analysis
        • 9.1.1 Global Plasma Protease C1-inhibitor Treatment Market Size (Volume and Value) Forecast 2019-2025
      • 9.2 Plasma Protease C1-inhibitor Treatment Regional Market Trend
        • 9.2.1 North America Plasma Protease C1-inhibitor Treatment Forecast 2019-2025
        • 9.2.2 Europe Plasma Protease C1-inhibitor Treatment Forecast 2019-2025
        • 9.2.3 China Plasma Protease C1-inhibitor Treatment Forecast 2019-2025
        • 9.2.4 Japan Plasma Protease C1-inhibitor Treatment Forecast 2019-2025
        • 9.2.5 Southeast Asia Plasma Protease C1-inhibitor Treatment Forecast 2019-2025
        • 9.2.6 India Plasma Protease C1-inhibitor Treatment Forecast 2019-2025
      • 9.3 Plasma Protease C1-inhibitor Treatment Market Trend (Product Type)
      • 9.4 Plasma Protease C1-inhibitor Treatment Market Trend (Application)
      • 10.1 Marketing Channel
        • 10.1.1 Direct Marketing
        • 10.1.2 Indirect Marketing
      • 10.3 Plasma Protease C1-inhibitor Treatment Customers

      11 Market Dynamics

      • 11.1 Market Trends
      • 11.2 Opportunities
      • 11.3 Market Drivers
      • 11.4 Challenges
      • 11.5 Influence Factors

      12 Conclusion

        13 Appendix

        • 13.1 Methodology/Research Approach
          • 13.1.1 Research Programs/Design
          • 13.1.2 Market Size Estimation
          • 13.1.3 Market Breakdown and Data Triangulation
        • 13.2 Data Source
          • 13.2.1 Secondary Sources
          • 13.2.2 Primary Sources
        • 13.3 Author List

        The global Plasma Protease C1-inhibitor Treatment market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025.
        This report focuses on Plasma Protease C1-inhibitor Treatment volume and value at global level, regional level and company level. From a global perspective, this report represents overall Plasma Protease C1-inhibitor Treatment market size by analyzing historical data and future prospect.
        Regionally, this report categorizes the production, apparent consumption, export and import of Plasma Protease C1-inhibitor Treatment in North America, Europe, China, Japan, Southeast Asia and India.
        For each manufacturer covered, this report analyzes their Plasma Protease C1-inhibitor Treatment manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

        The following manufacturers are covered:
        Shire plc
        CSL Limited
        Sanquin
        Pharming Group N.V.
        ...

        Segment by Regions
        North America
        Europe
        China
        Japan
        Southeast Asia
        India

        Segment by Type
        by Drug Class
        C1-inhibitors
        Kallikrein Inhibitor (Kalbitor)
        Selective Bradykinin B2 Receptor Antagonist (Firazyr)
        by Dosage Type
        Liquid/Injectable
        Lyophilized

        Segment by Application
        Hospital Pharmacies
        Independent Pharmacies and Outlets

        Buy now